As a consequence, BRCA1 associated breast cancers require a specially tailored therapeutic regimen, since the frequent lack of hormone receptors (ER/PR) or Her2 extensively narrows the application of (anti-)endocrine therapies [5]. The gene discussed is ESR1; the disease is breast carcinoma.